Global Approval Could Be On The Horizon For Orexigen's Weight Loss Drug

Contrave is a combination of bupropion sustained-release (SR) and Orexigen´s wholly owned SR version of naltrexone, designed to help patients lose weight. The addition of Naltrexone said to improve patient tolerability for the treatment. The company is …

via Get Fit Bookmark http://ift.tt/Xjo8ke

via Tumblr http://ift.tt/1uKvTi0